Responses
Regular and young investigator award abstracts
Cellular therapies
130 Immunogenic potential of chimeric antigen receptor (CAR)-engineered T cells expressing inducible nuclease-deactivated SpCas9 (dCas9)
Compose a Response to This Article
Other responses
No responses have been published for this article.
